A PHASE 1/2/3 MULTICENTER, OPEN LABEL STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, AND PHARMACODYNAMICS OF RGX-121 IN PEDIATRIC SUBJECTS WITH MPS II (HUNTER SYNDROME)
- Registry ID
- RGX-121-101
- Source registry
- HEALTH_CANADA
- Status
- Closed
- Phase
- PHASE1
- Study type
- INTERVENTIONAL
- Sponsor
- REGENXBIO INC
- Completion date
- 2026-02-27
- Last update
- 2022-10-26
Conditions
- HUNTER SYNDROME
- MUCOPOLYSACCHARIDOSIS TYPE II (MPS II)
Related clinical trials
- EFFECT OF ADALIMUMAB ON MUSCULOSKELETAL
DISEASE IN MUCOPOLYSACCHARIDOSIS TYPES I, II, IVA AND VI
- AN OPEN-LABEL EXTENSION FOR SUBJECTS IN STUDIES HGT-HIT-046 AND SHP609-302 EVALUATING
LONG-TERM SAFETY OF INTRATHECAL IDURSULFASE-IT ADMINISTERED IN CONJUNCTION WITH INTRAVENOUS
ELAPRASE® IN SUBJECTS WITH HUNTER SYNDROME AND COGNITIVE IMPAIRMENT
- AN OPEN-LABEL EXTENSION TO INVESTIGATE THE LONG-TERM SAFETY, TOLERABILITY, AND
EFFICACY OF DNL310 IN PATIENTS WITH MUCOPOLYSACCHARIDOSIS TYPE II (MPS II)
FROM STUDY DNLI-E-0002 OR STUDY DNLI-E-0007
- A PHASE 2/3, MULTICENTER, DOUBLE-BLIND, RANDOMIZED STUDY TO DETERMINE THE EFFICACY AND SAFETY OF DNL310 VS IDURSULFASE IN PEDIATRIC PARTICIPANTS WITH NEURONOPATHIC OR NON-NEURONOPATHIC MUCOPOLYSACCHARIDOSIS TYPE II
- A PHASE 1/2, MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF DNL310 IN PEDIATRIC SUBJECTS WITH HUNTER SYNDROME
- "AN OPEN LABEL EXTENSION OF STUDY HGT-HIT-094 EVALUATING LONG TERM SAFETY AND CLINICAL OUTCOMES OF INTRATHECAL IDURSULFASE ADMINISTERED IN CONJUNCTION WITH ELAPRASE IN PATIENTS WITH HUNTER SYNDROME AND COGNITIVE IMPAIRMENT."
View on source registry